India, Nov. 6 -- Ahmedabad-based Zydus, a leading, discovery-based, global pharmaceutical company, has announced that the USFDA has granted Orphan Drug Designation (ODD) to Desidustat, a novel oral HIF-PHI, for the treatment ofbeta-thalassemia.

The USFDA's Office of Orphan Drug Products grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 200,000 people in the United States.

Speaking on the development, Dr Sharvil Patel, Managing Director, Zydus Lifesciences Limited, said, "This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop Desidustat to address beta-thalassemia."

Beta thalassaemia patients have low levels of haemoglobin, which results ...